Promises and challenges of Smac mimetics as cancer therapeutics

Clinical Cancer Research

Volumn 21, Issue 22, 2015, Pages 5030-5036

  Fulda, Simone ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIRC2 PROTEIN, HUMAN; BIRC3 PROTEIN, HUMAN; DIABLO PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; MITOCHONDRIAL PROTEIN; SIGNAL PEPTIDE; UBIQUITIN PROTEIN LIGASE; X LINKED INHIBITOR OF APOPTOSIS;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOMIMETICS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; HUMAN; NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOMIMETICS; CLINICAL TRIALS AS TOPIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MITOCHONDRIAL PROTEINS; NEOPLASMS; UBIQUITIN-PROTEIN LIGASES; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84954110027     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0365     Document Type: Article

References (73)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
2. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006;25:4798-811.
3. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012;11:109-24.
4. Vucic D, Dixit VM, Wertz IE. Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol 2011;12:439-52.
5. Scheidereit C. IκB kinase complexes: gateways to NF-κB activation and transcription. Oncogene 2006;25:6685-705.
6. Chu WM. Tumor necrosis factor. Cancer Lett 2013;328:222-5.
7. Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng PH, Keats JJ, Wang H, et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIKdependent alternative NF-kappaB signaling. Nat Immunol 2008;9: 1364-70.
8. Zarnegar BJ, Wang Y, Mahoney DJ, Dempsey PW, Cheung HH, He J, et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 2008;9:1371-8.
9. Sun SC. Non-canonical NF-kappaB signaling pathway. Cell Res 2011; 21:71-85.
10. Varfolomeev E, Goncharov T, Maecker H, Zobel K, Komuves LG, Deshayes K, et al. Cellular inhibitors of apoptosis are global regulators of NF-kappaB and MAPK activation bymembers of the TNF family of receptors. Sci Signal 2012;5:ra22.
11. Birkey Reffey S, Wurthner JU, Parks WT, Roberts AB, Duckett CS. Xlinked inhibitor of apoptosis protein functions as a cofactor in transforming growth factor-beta signaling. J Biol Chem 2001;276: 26542-9.
12. Hofer-Warbinek R, Schmid JA, Stehlik C, Binder BR, Lipp J, de Martin R. Activation of NF-kappa B by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1. J Biol Chem 2000; 275:22064-8.
13. Beug ST, Cheung HH, Lacasse EC, Korneluk RG. Modulation of immune signalling by inhibitors of apoptosis. Trends Immunol 2012;33:535-45.
14. Lopez J, Meier P. To fight or die - inhibitor of apoptosis proteins at the crossroad of innate immunity and death. Curr Opin Cell Biol 2010; 22:872-81.
15. Gibson CJ, Davids MS. BCL-2 antagonism to target the intrinsic mitochondrial pathway of apoptosis. Clin Cancer Res 2015;21:5021-9.
16. LaCasse EC. Pulling the plug on a cancer cell by eliminating XIAP with AEG35156. Cancer Lett 2013;332:215-24.
17. Straub CS. Targeting IAPs as an approach to anti-cancer therapy. Curr Top Med Chem 2011;11:291-316.
18. Gao Z, Tian Y, Wang J, Yin Q, Wu H, Li YM, et al. A dimeric Smac/diablo peptide directly relieves caspase-3 inhibition by XIAP. Dynamic and cooperative regulation of XIAP by Smac/Diablo. J Biol Chem 2007; 282:30718-27.
19. Varfolomeev E, Alicke B, Elliott JM, Zobel K, West K, Wong H, et al. X chromosome-linked inhibitor of apoptosis regulates cell death induction by proapoptotic receptor agonists. J Biol Chem 2009;284:34553-60.
20. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, et al. IAP antagonists induce autoubiquitination of c-IAPs, NFkappaB activation, and TNFalpha-dependent apoptosis. Cell 2007; 131:669-81.
21. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007;131:682-93.
22. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smacmimetic-induced apoptosis. Cancer Cell 2007;12:445-56.
23. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008;30:689-700.
24. Dueber EC, Schoeffler AJ, Lingel A, Elliott JM, Fedorova AV, Giannetti AM, et al. Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination. Science 2011;334:376-80.
25. Ndubaku C, Varfolomeev E, Wang L, Zobel K, Lau K, Elliott LO, et al. Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists. ACS Chem Biol 2009;4: 557-66.
26. Infante JR, Dees EC, Olszanski AJ, Dhuria SV, Sen S, Cameron S, et al. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J Clin Oncol 2014;32: 3103-10.
27. Tolcher A, Papadopoulos K, Patnaik A, Fairbrother W, Wong H, Budha N, et al. Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma. J Clin Oncol 31, 2013 (suppl; abstr 2503).
28. Sikic BI, Eckhardt SG, Gallant G, Burris HA, Camidge DR, Covelas AD, et al. Safety, pharmocokinetics (PK), and pharmacodynamics (PD) of HGS1029, an inhibitor of apoptosis protein (IAP), in patients (Pts.) with advanced solid tumors: results of a phase I study. J Clin Oncol 29, 2011 (suppl; abstr 3008).
29. Amaravadi R, NN S, LP M, Schilder R, LoRusso P, Papadopoulos K, et al. A phase I study of birinapant (TL32711) combined with multiple chemotherapies evaluating tolerability and clinical activity for solid tumor patients. J Clin Oncol 31, 2013 (suppl; abstr 2504).
30. Senzer N, LoRusso P, Martin L, Schilder R, Amaravadi R, Papadopoulos K, et al. Phase II clinical activity and tolerability of the SMAC-mimetic birinapant (TL32711) plus irinotecan in irinotecan-relapsed/refractory metastatic colorectal cancer. J Clin Oncol 31, 2013 (suppl; abstr 3621).
31. Hurwitz H, Pitot H, Smith D, Brill J, Vuagniaux G, Rouits E, et al. First-inhuman, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results. J Clin Oncol 32:5s, 2014 (suppl; abstr 2532).
32. Fetterly G, Liu B, Senzer N, Amaravadi R, Schilder R, Martin L, et al. Clinical pharmacokinetics of the Smac-mimetic birinapant (TL32711) as a single agent and in combination with multiple chemotherapy regimens. J Clin Oncol 30, 2012 (suppl; abstr 3029).
33. Rouits E, Gisleskog P, Gavillet B, Menetrey A, Sorensen M, Zanna C, et al. Clinical pharmacokinetic (PK)/pharmacodynamic (PD) model for Debio 1143, a novel antagonist of IAPs in cancer treatment. J Clin Oncol 32:5s, 2014 (suppl; abstr 2585).
34. Bunch K, Noonan A, Lee J, O'Sullivan CCM, Houston N, Ekwede I, et al. Pharmacodynamic biomarkers from phase II study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-mimetic birinapant (TL32711; NSC 756502) in relapsed platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC) (NCT01681368). J Clin Oncol 32:5s, 2014 (suppl; abstr 5585).
35. Stadel D, Cristofanon S, Abhari BA, Deshayes K, Zobel K, Vucic D, et al. Requirement of nuclear factor kappaB for Smac mimetic-mediated sensitization of pancreatic carcinoma cells for gemcitabine-induced apoptosis. Neoplasia 2011;13:1162-70.
36. Loeder S, Fakler M, Schoeneberger H, Cristofanon S, Leibacher J, Vanlangenakker N, et al. RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. Leukemia 2012;26:1020-9.
37. Probst BL, Liu L, Ramesh V, Li L, Sun H, Minna JD, et al. Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-alpha-dependent manner. Cell Death Differ 2010;17:1645-54.
38. Dineen SP, Roland CL, Greer R, Carbon JG, Toombs JE, Gupta P, et al. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res 2010;70:2852-61.
39. Wagner L, Marschall V, Karl S, Cristofanon S, Zobel K, Deshayes K, et al. Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-kappaB-dependent manner. Oncogene 2013;32:988-97.
40. Chromik J, Safferthal C, Serve H, Fulda S. Smac mimetic primes apoptosisresistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis. Cancer Lett 2014;344:101-9.
41. Belz K, Schoeneberger H, Wehner S, Weigert A, Bonig H, Klingebiel T, et al. Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly. Blood 2014;124:240-50.
42. Vellanki SH, Grabrucker A, Liebau S, Proepper C, Eramo A, Braun V, et al. Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia 2009;11:743-52.
43. Giagkousiklidis S, Vellanki SH, Debatin KM, Fulda S. Sensitization of pancreatic carcinoma cells for gamma-irradiation-induced apoptosis by XIAP inhibition. Oncogene 2007;26:7006-16.
44. Berger R, Jennewein C, Marschall V, Karl S, Cristofanon S, Wagner L, et al. NF-{kappa}B is required for Smac mimetic-mediated sensitization of glioblastoma cells for {gamma}-irradiation-induced apoptosis. Mol Cancer Ther 2011;10:1867-75.
45. Ziegler DS, Keating J, Kesari S, Fast EM, Zawel L, Ramakrishna N, et al. A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo. Neuro Oncol 2011;13:820-9.
46. Fulda S. Inhibitor of Apoptosis (IAP) proteins as therapeutic targets for radiosensitization of human cancers. Cancer Treat Rev 2012;38:760-6.
47. Stadel D, Mohr A, Ref C, MacFarlane M, Zhou S, Humphreys R, et al. TRAILinduced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin Cancer Res 2010;16:5734-49.
48. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 2009;69:2425-34.
49. Loeder S, Zenz T, Schnaiter A, Mertens D, Winkler D, Dohner H, et al. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res 2009;69:8977-86.
50. Fakler M, Loeder S, Vogler M, Schneider K, Jeremias I, Debatin KM, et al. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood 2009;113:1710-22.
51. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002;8:808-15.
52. Cristofanon S, Abhari BA, Krueger M, Tchoghandjian A, Momma S, Calaminus C, et al. Identification of RIP1 as a critical mediator of Smac mimetic-mediated sensitization of glioblastoma cells for Drozitumabinduced apoptosis. Cell Death Dis 2015;6:e1724.
53. Abhari BA, Cristofanon S, Kappler R, von Schweinitz D, Humphreys R, Fulda S. RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex. Oncogene 2013;32:3263-73.
54. Basit F, Humphreys R, Fulda S. RIP1 protein-dependent assembly of a cytosolic cell death complex is required for inhibitor of apoptosis (IAP) inhibitor-mediated sensitization to lexatumumab-induced apoptosis. J Biol Chem 2012;287:38767-77.
55. Steinhart L, Belz K, Fulda S. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis. Cell Death Dis 2013;4:e802.
56. Carter BZ, Mak PY, Mak DH, Shi Y, Qiu Y, Bogenberger JM, et al. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. J Natl Cancer Inst 2014;106:djt440.
57. Steinwascher S, Nugues AL, Schoeneberger H, Fulda S. Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells. Cancer Lett 2015;366: 32-43.
58. Beug ST, Tang VA, LaCasse EC, Cheung HH, Beauregard CE, Brun J, et al. Smac mimetics and innate immune stimuli synergize to promote tumor death. Nat Biotechnol 2014;32:182-90.
59. Bake V, Roesler S, Eckhardt I, Belz K, Fulda S. Synergistic interaction of Smac mimetic and IFNalpha to trigger apoptosis in acute myeloid leukemia cells. Cancer Lett 2014;355:224-31.
60. Jinesh GG, Chunduru S, Kamat AM. Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-alpha but not through TRAIL and Fas L. J Leukoc Biol 2012;92:233-44.
61. Rettinger E, Glatthaar A, Abhari B, Oelsner S, Pfirrmann V, Huenecke S, et al. SMAC mimetic BV6 enables sensitization of resistant tumor cells but also affects cytokine-induced killer (CIK) cells: a potential challenge for combination therapy. Front Pediatr Onc 2014;2:75.
62. DiPersio J, Erba H, Larson R, Luger S, Mangan K, Tallman M, et al. Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML). J Clin Oncol 32:5s, 2014 (suppl; abstr 7029).
63. Weisberg E, Kung AL, Wright RD, Moreno D, Catley L, Ray A, et al. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Mol Cancer Ther 2007;6:1951-61.
64. Langdon CG, Wiedemann N, Held MA, Platt JT, Lévy F, Zanna C, et al., et al. A drug combination screen identifies taxanes as synergistic agents with the oral IAP inhibitor Debio 1143 in non-small cell lung cancer cells [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston (MA) and Philadelphia (PA): AACR; 2013: Abstract nr A16.
65. Viertl D, Perillo-Adamer F, Rigotti S, Maby El Hajjami H, Vaslin A, Vuagniaux G, et al. Preclinical rationale for combining the Smac-mimetic Debio 1143 with concurrent chemio-radiotherapy in La-SCCHN [abstract]. In: Proceedings of the 4th International Conference on Innovative Approaches in Head & Neck Oncology; 2013 Feb 7-9, Barcelona, Spain. Brussels (Belgium): European Society for Radiotherapy&Oncology; Radiother Oncol. 2013;106:S6-7. Abstract nr OC-019.
66. Le Tourneau C, Tao Y, Delord J, Brienza S, Vuagniaux G, Sablin M, et al. A phase I/II randomized study of Debio1143 combined with concurrent chemoradiation therapy (CCRT) in patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). J Clin Oncol 32:5s, 2014 (suppl; abstr TPS6097).
67. Fulda S. Molecular pathways: targeting death receptors and smac mimetics. Clin Cancer Res 2014;20:3915-20.
68. Petrucci E, Pasquini L, Petronelli A, Saulle E, Mariani G, Riccioni R, et al. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecol Oncol 2007;105:481-92.
69. Mao HL, Pang Y, Zhang X, Yang F, Zheng J, Wang Y, et al. Smac peptide potentiates TRAIL-or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo. Oncol Rep 2013;29:515-22.
70. Borthakur G, Foran J, Wang E, Rakkar A, Hager S, Frey N, et al. A phase 1b/2a study of birinapant in combination with 5-azacitadine in patients with myelodysplastic syndrome who are naïve, refractory to or have relapsed on 5-azacitadine: a preliminary analysis [abstract]. In: Proceedings of the 56th ASH Annual Meeting and Exposition; 2014 Dec 6-9; San Francisco, CA and Washington, DC: American Society of Hematology; 2014. Abstract nr 3263.
71. Tchoghandjian A, Jennewein C, Eckhardt I, Rajalingam K, Fulda S. Identification of non-canonical NF-kappaB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells. Cell Death Dis 2013;4:e564.
72. Tchoghandjian A, Jennewein C, Eckhardt I, Momma S, Figarella-Branger D, Fulda S. Smac mimetic promotes glioblastoma cancer stem-like cell differentiation by activating NF-kappaB. Cell Death Differ 2014;21: 735-47.
73. Firestone B, Conway C, Yang G, Gao H, Porter D, Slisz J, et al. Correlation between TNFα and LCL161 anti-tumor activity in patient derived xenograft models of human cancer [abstract]. Mol Cancer Ther 2009;8(12 Suppl): B27.